Two academic authors of the ADVOCATE study requested retraction, citing the US FDA drugs center’s finding that primary endpoint assessments in nine patients were readjudicated after unblinding.
Two academic authors of the ADVOCATE study requested retraction, citing the US FDA drugs center’s finding that primary endpoint assessments in nine patients were readjudicated after unblinding.